Clinical Trials Logo

Narcotic Abuse clinical trials

View clinical trials related to Narcotic Abuse.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT02925806 Enrolling by invitation - Drug Abuse Clinical Trials

Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products

Start date: n/a
Phase: N/A
Study type: Observational

A drug utilization study will be performed to describe trends in the number of prescriptions and patients for class REMS ER/LA opioids and comparator products.

NCT ID: NCT02920775 Enrolling by invitation - Drug Abuse Clinical Trials

Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics

Start date: n/a
Phase: N/A
Study type: Observational

Changes in prescribing will be compared in prescribers from specialties whose prescribing is hypothesized to be relatively unaffected by the REMS (such as oncologists and hospice providers) versus those for whom the REMS could have greater impact on prescribing (e.g., dentists). Trends and changes in monthly prescription volume and average monthly prescription volume will be evaluated by prescriber specialty.

NCT ID: NCT02920762 Enrolling by invitation - Drug Abuse Clinical Trials

Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers

Start date: n/a
Phase: N/A
Study type: Observational

A study will be performed to evaluate changes in prescribing behavior of prescribers of ER/LA opioids

NCT ID: NCT02871232 Enrolling by invitation - Clinical trials for Opioid-related Disorders

Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers

Start date: n/a
Phase: N/A
Study type: Observational

To conduct surveillance for abuse, misuse, overdose, addiction, and death and to evaluate if the REMS meets its surveillance goals, and if it does not, to modify it appropriately based on the metrics. Briefly, therefore, the overall surveillance objective is to evaluate for trends before and after the shared REMS is implemented to collectively assess for changes in abuse, misuse, overdose, addiction, and death for different risk groups and settings.